Investigation of a New Stoma Product for People With a Stoma (CP288)

Coloplast

Status: Completed

Conditions: Peristomal Skin Complication

Treatments: Device: Non-Conformité Européene marked product; Device: Conformité Européene marked competitor products

Study type: Interventional

Funder types: Industry

Identifiers

NCT04101318

CP288

Details and patient eligibility

About

The CP288 study is an investigation of a non-Conformité Européene marked stoma product which will be conducted in the UK, Italy, Netherlands, Germany, and Norway. The study will enroll up to 100 subjects. The study is a randomized, open-label, comparative study.

Full description

Enrolled participant with an ileostomy or colostomy with liquid output were randomized to test either the non-Conformité Européene marked investigational product or one of the five comparators Conformité Européene marked products first and then will be crossed over to receive the opposite intervention.

The participant will first be included in an information and inclusion visit (V0) and after signing all consent forms will complete three test visits (V1, V2, and V3). Each participant will be enrolled for 2 × 42±3 days in total for the entire investigation, thus for a maximum of 90 days.

The study is a randomised, controlled, open-label, comparative, cross-over, multicentre investigation with two test periods. The study was conducted in four different countries (UK, Germany, Italy, and Norway) with a total of six sites participating.

The study is now complete.

Enrollment: 79 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Has given informed consent to participate by signing the informed consent signature form.

2. Has an ileostomy or colostomy with liquid output (defined by a 6-7 on the Bristol Scale)

3. Currently using a flat product

4. Be at least 18 years of age and have full legal capacity

5. Have had their stoma for at least three months (90 days)

6. Can use a product with a max cut size of 40 mm

7. Has experienced leakage* under the baseplate at least three times within the last 14 days. *leakage defined as output seeping under the baseplate (Appendix 6 - Classification of leakage)

8. Has symptoms of peristomal skin complications or has peristomal skin complications defined by at least one of the below

   1. Has experienced symptoms of skin complications (itching, burning, pain) within the last fourteen days
   2. Has experienced red skin in the inner circle (within three cm from stoma edge) within the last fourteen days
   3. Has skin complication (assessed by Principal Investigator, or delegate) in the inner circle (within three cm from stoma edge) of the peristomal area

9. Is able to handle the electronic diary (questionnaire/ photo) themselves.

10. Is able to handle (apply, remove, cut etc.) the product themselves

11. Is willing to not use barrier film or barrier cream during the investigation

12. Is willing and suitable (determined by Principal Investigator, or delegate) to use a flat custom cut one-piece open or a two-piece open product during the investigation.

13. Is willing to change the product (1pc) or baseplate (2pc) at least every fourth days.

Exclusion criteria

1. Is currently receiving or have within the past 60 days received radio-and/or chemotherapy

   • low doses chemotherapy (assessed by Principal Investigator) is allowed for indications other than cancer.

2. Is currently receiving or have within the past month received topical steroid treatment in the peristomal skin area, e.g. lotion or spray.

   • Low dose systemic steroid treatment (e.g. inhalation) assessed by the Principal Investigator are allowed.
   • Other systemic steroid treatment (e.g. injection, or tablet) are not allowed.

3. Is breastfeeding

4. Is pregnant (based on pregnancy test -urine)

5. Has known hypersensitivity towards any of the products used in the investigation

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

79 participants in 2 patient groups

The non-Conformité Européene marked product, a Conformité Européene marked product

Experimental group

Description:

Participants first received the non-Conformité Européene marked investigational product for 42±3 days. Then there was a cross-over and the participants received one of the five Conformité Européene marked comparators products, which they used the following 42±3 days.

Treatment:

Device: Conformité Européene marked competitor products

Device: Non-Conformité Européene marked product

A Conformité Européene marked product, then the non-Conformité Européene marked product

Experimental group

Description:

Participants first received one of the five Conformité Européene marked comparators products for 42±3 days. Then there was a cross-over and the participants received the non-Conformité Européene marked investigational products, which they used the following 42±3 days.

Treatment:

Device: Conformité Européene marked competitor products

Device: Non-Conformité Européene marked product